Keryx Biopharma (KERX) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Nvidia to commit $3 bln to Meta share offering as part of bigger AI partnership
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Boeing free cash flow beats estimates despite production challenges
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharma (NASDAQ: KERX) reported Q3 EPS of ($0.38), $0.11 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $256 thousand versus the consensus estimate of $150 thousand.
For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning shares rise 3% in premarket trade after Q3 EPS, revenue beat estimates
- Boeing free cash flow beats estimates despite production challenges
- Ecolab (ECL) Tops Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
